The role of proton pump inhibitors in the treatment of gastro‐oesophageal reflux disease

Alimentary Pharmacology & Therapeutics

Volumn 9, Issue , 1995, Pages 15-25

  BARDHAN, K D ^a  

^a ROTHERHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

ANTI-ULCER AGENTS; CLINICAL TRIALS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMAN; PROTON PUMPS; RECURRENCE; WOUND HEALING;

EID: 0029066718     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1995.tb00779.x     Document Type: Article

References (73)

1. 2 antagonists in the treatment of reflux esophagitis: A criticial analysis
2. Rolling review: gastro‐oesophageal reflux disease
3. Review article: drug therapy for reflux esophagitis
4. Omeprazole in the treatment of gastroesophageal reflux disease
5. Appropriate acid suppression for the management of gastroesophageal reflux disease
6. Omeprazole or ranitidine in the treatment of reflux esophagitis
7. Omeprazole is superior to ranitidine in the treatment of reflux esophagitis
8. Omeprazole (20 mg om) vs ranitidine (150 mg bid) in reflux esophagitis. Results of a double‐blind randomised trial
9. Comparison of omeprazole and cimetidine in reflux esophagitis: symptomatic, endoscopic and histological evaluations
10. Reflux esophagitis resolves more rapidly with omeprazole 20 mg once daily than with ranitidine 150 mg twice daily Omeprazole 40 mg once daily produces further benefit in unresponsive patients
11. Frame M H on behalf of the Italian Reflux Oesophagitis Study Group Oesophagitis produces significantly greater healing of erosive oesophagitis or ulcerative reflux oesophagitis than ranitidine
12. Omeprazole vs ranitidine in the treatment of symptomatic mild reflux oesophagitis. A Dutch multi‐centre trial
13. Groupe d'etude Omega Cost‐effectiveness comparison between omeprazole and ranitidine for treatment for reflux esophagitis
14. Lansoprazole, a new proton pump blocker, vs ranitidine in the treatment of reflux esophagitis
15. Lansoprazole and ranitidine in treatment of reflux oesophagitis: double‐blind comparative trial
16. Greski‐Rose P, and The Lansoprazole Study Group Lansoprazole heals erosive reflux esophagitis better than ranitidine
17. Different healing tendencies of reflux esophagitis following omeprazole and ranitidine Results of a German‐Austrian‐Swiss multicentre study
18. Omeprazole and ranitidine in treatment of reflux esophagitis: Double blind comparative trial
19. Omeprazole (40 mg) is superior to ranitidine in short‐term treatment of ulcerative reflux esophagitis
20. Double‐blind comparison of omeprazole (40 mg od) vs cimetidine (400 mg qd) in the treatment ofsymptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring
21. Double‐blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux esophagitis
22. Omeprazole 20 mg or 40 mg daily for the treatment of gastroesophageal reflux disease
23. Lansoprazole in acute treatment of reflux esophagitis
24. Lansoprazole vs omeprazole in short‐term trcatment of reflux oesophagitis. Results of a Scandinavian multicentre trial
25. Clinical effect of proton pump inhibitors on reflux esophagitis
26. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d with 300 mg ranitidine q.d.s
27. Ranitidine is effective in treating erosive esophagitis
28. Rubin A and The Glaxo Erosive Esophagitis Study Croup Ranitidine for erosive oesophagitis: a double blind placebo‐controlled study
29. Acid suppression in the long term treatment of peptic stricture and Barrett's oesophagitis
30. 2 receptor antagonists or omeprazole
31. 2 receptor antagonists
32. 2‐receptor antagonists and ineligible for surgery
33. +‐ATPase inhibitor: A controlled double blind study
34. Is there any acid peptic disease that is refractory to proton pump inhibitors
35. 2 receptor antagonists
36. Omeprazole or ranitidine at standard or double doses in the treatment of patients with refractoryrefluxesophagitis
37. 2‐receptor antagonist therapy
38. 2‐resistant erosive reflux esophagitis
39. Poynard T, and The French Cooperative Study Group Fate of patients after healing of oesophagitis. A prospective study of 1030 patients during 6 months
40. Lansoprazole heals moderate to severe reflux esophagitis
41. Verlinden M and the EUROCIS trialists. Cisapride prevents relapse of reflux esophagitis
42. Healing and prevention of relapse of reflux oesophagitis by cisapride
43. Effect of cisapride on relapse of reflux esophagitis healed with an antisecretory drug
44. Healing and relapse of reflux esophagitis during treatment with ranitidine
45. Treatment of reflux esophagitis: results of a multicentre study
46. Ranitidine vs placebo in long‐term treatment of gastroesophageal reflux (GERD)
47. Controlling 24 h esophageal acid exposure in patients with healed erosive esophagitis prevents endoscopic recurrence and symptomatic deterioration: results of a 6 month, randomized double blind placebo‐controlled trial comparing farnotidine 20 mg bid and 40 mg bid
48. Dekkcr W for The Dutch Esophagitis Study Group The efficacy of farnotidine 20 mg bid vs. 40 mg bid in the treatmcnt of erosive/ulcerative reflux esophagitis: significance of severity of esophagitis and duration of therapy
49. Comparison of two dosage regimens of omeprazole 10 mg once daily and 20 mg weekends as prophylaxis against recurrence of reflux esophagitis
50. Omeprazole 10 mg or 20 mg daily for the prevention of relapse in gastroesophageal reflux disease? A double blind comparative study
51. Omeprazole or ranitidine in the long‐term treatment of refractory esophagitis
52. Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety
53. Multicenter study on five long‐term treatments for reflux esophagitis
54. Lansoprazole is superior to ranitidine 300 mg bd in prevention of relapse of reflux oesophagitis
55. and The Lansoprazole Study Group Lansoprazole for one year prevents recurrence of erosive reflux esophagitis
56. 2RA resistant esophagitis—clinical, gastrin and ECL effects for up to 3 years
57. 2RA‐refractory erosive esophagitis (REE): Efficacy of long term omeprazole
58. Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine
59. Lansoprazole for one year prevents recurrence of resistant erosive reflux esophagitis
60. 2 antagonists, healing with omeprazole
61. Efficacy and safety of omeprazole in the long term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine
62. Ranitidine 300 mg once daily after dilatation of A peptic oesophageal strictures one‐year placebo‐controlled follow‐up study
63. 2‐receptor antagonists in treating patients with peptic stricture and esophagitis
64. Prevention of recurrence of esophageal stricture A comparative study of lansoprazole and high dose ranitidine
65. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases
66. Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease
67. Cost effectiveness of orneprazole in the treatment of reflux oesophagitis
68. 2‐receptor antagonists
69. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks oftreatment for symptomatic reflux oesophagitis
70. Cost effectiveness of 20 mg and 40 mg of omeprazole in oesophageal reflux disease
71. Cost effectiveness management strategies for acid‐peptic disorders
72. A one year model for the costeffectiveness of treating reflux oesophagitis
73. Assessing the cost‐effectiveness of medical treatments in acid‐related diseases